Suven Life Sciences is stepping up its push in the Alzheimer’s disease treatment space.
The pharma company is making two scientific presentations on its investigational drug candidates, Masupirdine (SUVN-502) and Tenaclidine (SUVN-I6107), at the 19th Clinical Trials on Alzheimer’s Disease (CTAD-2026) Conference in Boston, USA.
The presentations spotlight progress in two clinical programmes targeting significant unmet needs in central nervous system (CNS) disorders.
A key highlight is data from the global Phase-3 clinical study of Masupirdine, which is being investigated for agitation in patients with dementia of Alzheimer’s type. The presentation details the baseline demographic and clinical characteristics of patients enrolled in the study.
The company is also presenting first-in-human Phase-1 findings for Tenaclidine, a potential M1 positive allosteric modulator. The data covers safety, tolerability and pharmacokinetics from single ascending dose (SAD) and multiple ascending dose (MAD) studies in healthy volunteers, including the impact of food, age and gender on the drug’s pharmacokinetic profile.
Suven’s two presentations at CTAD-2026 are:
P033 – Masupirdine (SUVN-502): Baseline Demographic and Clinical Characteristics of the Phase-3 Clinical Study Targeting Agitation in Patients with Dementia of Alzheimer’s Type.
P066 – Tenaclidine (SUVN-I6107): First-in-Human Evaluation of Safety, Tolerability and Pharmacokinetics in Healthy Subjects.
The announcement comes as Suven reports completion of enrolment in the global Phase-3 Masupirdine AAD study, with topline results expected in the second quarter of 2027.
Highlighting the significance of the clinical milestones, Venkat Jasti, Chairman and Managing Director of Suven Life Sciences, said: "Completion of enrolment in the global Phase-3 Masupirdine AAD study marks an important milestone in the clinical development. Very glad to report the baseline characteristics are consistent with the published studies, representative of quality AD population with Agitation and no major safety concerns have been identified to date.
"We look forward to the topline results as scheduled in Q2-2027. We are very encouraged by the clinical findings for Tenaclidine, to move forward to the patient studies. The progress reflects our continued efforts to advance innovative therapeutic approaches addressing significant unmet needs in CNS disorders"
The CTAD conference brings together clinical investigators, healthcare professionals, pharmaceutical industry scientists and regulatory experts from across the world to discuss advances in Alzheimer’s disease research, prevention and treatment.